My theory is still UNIS's future financing is tied to dupilumab being approved. It will be tested shortly as UNIS is out of $$$ having just looked at the 2Q 2017 balance sheet.
If we receive further funding on decent terms that is probably thanks to dupilumab heading to our WI's. If the funding is draconian then we can draw conclusions as to where we stand. The universe of possibility is quite small.
Either way the wait is about over and a resolution to UNIS's future will be known.
UNS Price at posting:
4.0¢ Sentiment: Buy Disclosure: Held
